Rain Oncology Inc (RAIN)

[axelvento]

There's one piece left-- Rain Therapeutics Provides Interim Analysis of Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)

- Two patients exhibited an unconfirmed partial response at their first scan, and two additional patients saw promising tumor regression activity out of ten efficacy evaluable patients, demonstrating monotherapy activity of milademetan in MDM2-amplified patients -

At the data cutoff of October 26, 2022, 17 patients were enrolled. Two unconfirmed partial responses were observed in patients with pancreatic and lung cancer with a tumor regression of 34% and 30% with lung cancer, respectively. Additionally, there was promising tumor regression of 29% in a patient with biliary tract cancer and 27% in a patient with breast cancer; both are receiving continued investigational therapy.

https://www.rainoncology.com/news-press-releases/rain-therapeutics-provides-interim-analysis-of-phase-2-basket-trial-of-milademetan-for-mdm2-amplified-advanced-solid-tumors-mantra-2